Université de Paris, France; Innovative Therapies in Haemostasis, INSERM, F-75006 Paris, France; Biosurgical research lab (Carpentier Foundation), F-75015 Paris, France; Department of Respiratory Medicine, France; Assistance publique hôpitaux de Paris AH-HP, Hôpital européen Georges-Pompidou, F-75015 Paris, France.
Department of Radiology, France; Groupe Hospitalier Paris Saint-Joseph, F-75014 Paris, France.
Thromb Res. 2021 Jan;197:94-99. doi: 10.1016/j.thromres.2020.11.001. Epub 2020 Nov 7.
Coronavirus disease 2019 (COVID-19) has been associated with cardiovascular complications and coagulation disorders. Previous studies reported pulmonary embolism (PE) in severe COVID-19 patients. Aim of the study was to estimate the prevalence of symptomatic PE in COVID-19 patients and to identify the clinical, radiological or biological characteristics associated with PE.
PATIENTS/METHODS: We conducted a retrospective nested case-control study in 2 French hospitals. Controls were matched in a 1:2 ratio on the basis of age, sex and center. PE patients with COVID-19 were compared to patients in whom PE was ruled out (CTPA controls) and in whom PE has not been investigated (CT controls).
PE was suspected in 269 patients among 1042 COVID-19 patients, and confirmed in 59 patients (5.6%). Half of PE was diagnosed at COVID-19 diagnosis. PE patients did not differ from CT and CTPA controls for thrombosis risk factors. PE patients more often required invasive ventilation compared to CTPA controls (odds ratio (OR) 2.79; 95% confidence interval (CI) 1.33-5.84) and to CT controls (OR 8.07; 95% CI 2.70-23.82). PE patients exhibited more extensive parenchymal lesions (>50%) than CT controls (OR 3.90; 95% CI 1.54-9.94). D-dimer levels were 5.1 (95% CI 1.90-13.76) times higher in PE patients than CTPA controls.
Our results suggest a PE prevalence in COVID-19 patients close to 5% in the whole population and to 20% of the clinically suspected population. PE seems to be associated with more extensive lung damage and to require more frequently invasive ventilation.
2019 年冠状病毒病(COVID-19)与心血管并发症和凝血障碍有关。先前的研究报告了重症 COVID-19 患者发生肺栓塞(PE)。本研究旨在评估 COVID-19 患者中症状性 PE 的患病率,并确定与 PE 相关的临床、放射学或生物学特征。
患者/方法:我们在法国的 2 家医院进行了一项回顾性巢式病例对照研究。基于年龄、性别和中心,按 1:2 的比例对对照组进行匹配。COVID-19 患者中 PE 患者与排除 PE(CTPA 对照组)和未调查 PE(CT 对照组)的患者进行比较。
在 1042 例 COVID-19 患者中,有 269 例疑似 PE,其中 59 例(5.6%)确诊。一半的 PE 在 COVID-19 诊断时诊断出。PE 患者与 CTPA 和 CT 对照组在血栓形成危险因素方面无差异。与 CTPA 对照组(比值比(OR)2.79;95%置信区间(CI)1.33-5.84)和 CT 对照组(OR 8.07;95%CI 2.70-23.82)相比,PE 患者更常需要有创通气。PE 患者的实质病变范围比 CT 对照组更广泛(>50%)(OR 3.90;95%CI 1.54-9.94)。PE 患者的 D-二聚体水平比 CTPA 对照组高 5.1 倍(95%CI 1.90-13.76)。
我们的研究结果表明,在整个人群中,COVID-19 患者的 PE 患病率接近 5%,在临床上疑似人群中则为 20%。PE 似乎与更广泛的肺损伤有关,并更常需要有创通气。